Publication Name	World Journal of Gastroenterology
Manuscript ID	76810
Country	Japan

Received	2022-04-01 08:39
Peer-Review Started	2022-04-01 08:41
To Make the First Decision
Return for Revision	2022-05-09 06:34
Revised	2022-06-06 03:12
Second Decision	2022-06-29 03:14
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-06-30 22:58
Articles in Press	2022-06-30 22:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-07-01 06:09
Publish the Manuscript Online	2022-07-27 02:48

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment
Manuscript Source	Invited Manuscript
All Author List	Arata Nishimoto
ORCID	Author(s) ORCID Number Arata Nishimoto http://orcid.org/0000-0002-7406-0247
Funding Agency and Grant Number
Corresponding Author	Arata Nishimoto, PhD, Professor, Division of Basic Pharmaceutical Science, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-dori , Sanyo-Onoda City 756-0884, Yamaguchi, Japan. anishimo@rs.socu.ac.jp
Key Words	Pancreatic cancer; Gemcitabine; Targeted drug; Combination therapy
Core Tip	Gemcitabine has been the standard chemotherapy drug for patients with pancreatic cancer; however, its effectiveness is limited. Therefore, various combination therapies involving gemcitabine and targeted drugs are being explored. A review of combination therapies based mainly on clinical studies has been published recently; therefore, this minireview focuses on the findings of basic studies and discusses combinations of gemcitabine and targeted drugs, combinations of targeted drugs, combinations of natural products and anti-cancer agents, including gemcitabine, and combinations among natural products.
Publish Date	2022-07-27 02:48
Citation	Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643
URL	https://www.wjgnet.com/1007-9327/full/v28/i28/3637.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i28.3637

Full Article (PDF)	WJG-28-3637.pdf
Full Article (Word)	WJG-28-3637.docx
Manuscript File	76810_Auto_Edited-LM.docx
Answering Reviewers	76810-Answering reviewers.pdf
Audio Core Tip	76810-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	76810-Conflict-of-interest statement.pdf
Copyright License Agreement	76810-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	76810-Language certificate.pdf
Peer-review Report	76810-Peer-review(s).pdf
Scientific Editor Work List	76810-Scientific editor work list.pdf